Smith & Nephew PLC (SN.)
Industry Medical Devices
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
1,196.00p
Buy
1,197.00p
-9.50p (-0.79%)
Prices updated at 16 Dec 2025, 14:46 GMT
| Prices minimum 15 mins delay
Prices in GBX
Smith & Nephew PLC designs, manufactures, and markets orthopedic devices and wound-care solutions. Its products include knee replacements, hip implants, nails, fixation devices, arthroscopy tools and others.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 5,549m | 5,810m | |
| 3,819m | 4,046m | |
| 620m | 860m | |
| 11.17 | 14.80 | |
| 263m | 412m | |
| 956m | 1,221m | |
| Sales, General and administrative | 2,602m | 2,652m |
| Interest expenses | 139m | 168m |
| Provision for income taxes | 27m | 86m |
| Operating expenses | 3,199m | 3,186m |
| Income before taxes | 290m | 498m |
| Net income available to common shareholders | 263m | 412m |
| 0.302 | 0.472 | |
| Net interest income | -105m | -149m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | 0.301 | 0.47 |
| Free cash flow per share | 0.0198 | 0.2747 |
| Book value/share | 4.7143 | 4.7489 |
| Debt equity ratio | 0.444508 | 0.618803 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 4,030m | 4,421m |
| Current liabilities | 2,271m | 1,531m |
| Total capital | 7,392m | 8,388m |
| Total debt | 3,084m | 3,321m |
| Total equity | 5,217m | 5,265m |
| Total non current liabilities | - | - |
| Loans | 2,175m | 3,123m |
| Total assets | 9,987m | 10,354m |
| Total liabilities | - | - |
| Cash and cash equivalents | 302m | 619m |
| Common stock | 872m | 873m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 344m | 300m |
| Cash dividends paid | -327m | -327m |
| 181m | 606m | |
| Investments (gains) losses | -448m | -569m |
| 300m | 617m | |
| Net income | - | - |
| 608m | 987m | |
| -427m | -381m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.